Author: Maroun, Justin; Muñoz-Alía, Miguel; Ammayappan, Arun; Schulze, Autumn; Peng, Kah-Whye; Russell, Stephen
Title: Designing and building oncolytic viruses Document date: 2017_3_31
ID: qr1gsmqw_79
Snippet: In an OV-treated patient pre-existing antiviral immunity can be a formidable barrier to efficacy, particularly if the virus is administered intravenously. However, pre-existing antiviral immunity in caregivers and patient contacts provides reassuring protection against virus transmission. Conversely, when this particular efficacy barrier is circumvented by using OVs engineered for antibody evasion or selected for low seroprevalence, the risk of e.....
Document: In an OV-treated patient pre-existing antiviral immunity can be a formidable barrier to efficacy, particularly if the virus is administered intravenously. However, pre-existing antiviral immunity in caregivers and patient contacts provides reassuring protection against virus transmission. Conversely, when this particular efficacy barrier is circumvented by using OVs engineered for antibody evasion or selected for low seroprevalence, the risk of epidemic spread in the human population, unchecked by pre-existing herd immunity, looms larger.
Search related documents:
Co phrase search for related documents- antiviral immunity and herd immunity: 1, 2, 3, 4, 5, 6
- antiviral immunity and human population: 1, 2, 3, 4, 5
- antiviral immunity and virus transmission: 1, 2, 3, 4
- epidemic risk and herd immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- epidemic risk and human population: 1, 2, 3, 4, 5, 6, 7
- epidemic risk and low seroprevalence: 1
- epidemic risk and patient contact: 1, 2, 3
- epidemic risk and virus transmission: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
Co phrase search for related documents, hyperlinks ordered by date